Search results
Results from the WOW.Com Content Network
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. [10] It is used to prevent rabies following exposure. [10] It is given after the wound is cleaned with soap and water or povidone-iodine and is followed by a course of rabies vaccine. [10]
If the rosette test is negative, then a dose of 300 micrograms of RhIG is given (sufficient to prevent alloimmunization after delivery in 99% of cases). [11] [19] The RhIG dose suppresses the immune response to up to 30 cc of whole fetal blood (15 cc of red blood cells). If a fetomaternal hemorrhage in excess of 30 cc has occurred, additional ...
In the UK, one dose of HRIG costs the National Health Service £1,000, [88] although this is not flagged as a "high-cost medication". [89] A full course of vaccine costs £120–180. [ 90 ] As much as possible of HRIG should be injected around the bites, with the remainder being given by deep intramuscular injection at a site distant from the ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
The first report of immunizing an animal of one species (guinea pig) against the immune cells of another species (mouse lymphocytes) was by Élie Metchnikoff in 1899. He reported injecting cells recovered from mouse lymph nodes into Guinea pigs and waiting for the immunization to result in the accumulation of anti-mouse antibodies in the Guinea pig blood.
A Guideline Comparison utility that gives users the ability to generate side-by-side comparisons for any combination of two or more guidelines; Guideline Syntheses prepared by NGC staff, comparing guidelines covering similar topics, highlighting areas of similarity and difference.
The FDA approved the drug under the brand name RhoGAM, with a fixed dose of 300 μg, to be given within three days (72 hours) postpartum. Subsequently, a broader peripartum period was approved for dosing which included prophylaxis during pregnancy. Within a year, the antibody had been injected with great success into more than 500,000 women.
In the 1980s, the European Union began harmonising regulatory requirements. In 1989, Europe, Japan, and the United States began creating plans for harmonisation. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990 at a meeting in Brussels.